Mitsubishi UFJ Trust & Banking Corp Invests $4.59 Million in Medline $MDLN

Key Points

• Mitsubishi UFJ Trust & Banking Corp opened a new Q4 position in Medline of 109,359 shares valued at about $4.59 million, joining much larger new stakes from institutions including Vanguard (~$793.3M), Baillie Gifford (~$437.2M) and Massachusetts Financial Services (~$429.5M).
• Medline beat revenue expectations with $7.79 billion in Q4 revenue (up 14.8% YoY) but posted an EPS miss of ($0.01) versus the $0.24 consensus.
• Analyst sentiment is broadly positive with a consensus rating of "Moderate Buy" and an average price target of $50.62, alongside recent target increases from firms such as UBS ($57) and Morgan Stanley ($52).

Mitsubishi UFJ Trust & Banking Corp bought a new position in Medline (NASDAQ:MDLN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 109,359 shares of the company's stock, valued at approximately $4,593,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. acquired a new position in shares of Medline in the 4th quarter worth approximately $793,278,000. Baillie Gifford & Co. acquired a new position in shares of Medline in the 4th quarter worth approximately $437,236,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Medline in the 4th quarter worth approximately $429,544,000. UBS Group AG acquired a new position in shares of Medline in the 4th quarter worth approximately $54,707,000. Finally, Pictet Asset Management Holding SA acquired a new position in shares of Medline in the 4th quarter worth approximately $48,996,000.

Medline Price Performance

Shares of Medline stock opened at $44.75 on Monday. The company's fifty day simple moving average is $44.81. Medline has a 52 week low of $34.89 and a 52 week high of $50.88.

Medline (NASDAQ:MDLN - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.24 by ($0.25). The business had revenue of $7.79 billion for the quarter, compared to the consensus estimate of $7.52 billion. Medline's revenue was up 14.8% on a year-over-year basis. As a group, sell-side analysts forecast that Medline will post 1.46 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on MDLN shares. Wall Street Zen raised Medline to a "hold" rating in a report on Saturday, January 10th. Morgan Stanley boosted their target price on Medline from $48.00 to $52.00 and gave the stock an "overweight" rating in a report on Monday, March 2nd. UBS Group boosted their target price on Medline from $48.00 to $57.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. Barclays began coverage on shares of Medline in a research report on Monday, January 12th. They issued an "overweight" rating and a $50.00 price objective for the company. Finally, BMO Capital Markets boosted their price objective on shares of Medline from $45.00 to $54.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $50.62.

Medline Company Profile

Medline NASDAQ: MDLN is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

Want to see what other hedge funds are holding MDLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medline (NASDAQ:MDLN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.